# Enlaza Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enlaza-therapeutics

- Industry: Biotechnology
- Headquarters: La Jolla, US
- Website: www.enlazatx.com
- Total disclosed funding: $196M
- Latest round: Series A (Apr 30, 2024)
- Investors on record: 10

## About

Founded in 2020 by its Chief Executive Officer, Sergio Duron, president and chief business officer, Sanford (Sandy) Madigan, and based in California, US, Enlaza Therapeutics, Inc., operates as a biotechnology company that develops protein therapeutics to create drugs for cancer and other serious diseases. In March 2021, Enlaza Therapeutics, Inc., raised USD 35.30 million in seed funding from Avalon Ventures, with participation from other investors, Frazier Healthcare Partners, Lightspeed Venture Partners, and Samsara BioCapital. The company offers a healthcare platform, War-LockTM, that provides protein therapeutics used for the treatment of cancer and other serious diseases by minimizing exposure to healthy tissues. The drug is influenced by the company's proprietary amino acid subunits, which form a covalent bond between the drug and the target. The company plans to use March 2021 funding to further develop its War-LockTM platform and therapeutics research. In April 2024, Enlaza Therapeutics, Inc. raised USD 100 million in series A funding led by JP Morgan Asset Management, with participation from Alexandria Venture Investments, Amgen Ventures, Avalon Ventures, Bregua Corporation, Frazier Healthcare Partners, Lightspeed Venture Partners, Pappas Capital, Regeneron Pharmaceuticals, Inc., and Samsara BioCapital.

## Funding rounds

- Series A, Apr 30, 2024, $100M — Frazier Healthcare Partners, Lightspeed Venture Partners, Avalon Ventures, Pappas Capital, Alexandria Venture Investments, Amgen Ventures, JP Morgan Asset Management, Bregua Corporation, Samsara BioCapital, Regeneron Pharmaceuticals, Inc.
- Seed, Nov 22, 2022, $35M — Frazier Healthcare Partners, Lightspeed Venture Partners, Avalon Ventures, Samsara BioCapital
- Seed, Mar 12, 2021, $61M — Frazier Healthcare Partners, Lightspeed Venture Partners, Avalon Ventures, Samsara BioCapital

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Seed, Series A
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Seed, Series A
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Seed, Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Seed, Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series A
- Bregua Corporation — Series A
- Regeneron Pharmaceuticals, Inc. — Series A